VALOR-HCM: mavacamten significantly reduced guideline eligibility for invasive septal reduction therapy vs placebo at Week 16, sustained through to Week 56^1–3

Primary endpoint

Adapted from Desai MY et al. 2022.²

*Background therapies included beta blockers, calcium channel blockers, and disopyramide. Only 5.4% (3/56) of patients on each treatment arm did not receive any background medication due to intolerance.^2,3

The primary endpoint was a composite of patient decision to proceed with SRT prior to or at Week 16 or patients who remain SRT eligible (defined as a LVOT gradient of ≥50 mmHg and NYHA class III-IV, or class II with exertional syncope or near syncope) at Week 16¹

82%

(46/56) of patients treated with mavacamten were guideline ineligible for SRT or decided not to proceed with SRT at Week 16 vs 23% (13/56) of patients on placebo^1,2

^~4x

fewer patients met guideline criteria for SRT or chose to undergo SRT with mavacamten vs placebo at Week 16¹

Mavacamten continued to reduce guideline eligibility for invasive SRT at Week 56, including in patients who crossed over from placebo at Week 16*³

Treatment difference, 53.5%; 95% CI: 42 to 65

Adapted from Desai MY et al. 2023.³

*The average exposure duration to mavacamten at Week 56 for patients who crossed over from placebo at Week 16 was 40 weeks.³
^†Background therapies included beta blockers, calcium channel blockers, and disopyramide. Only 5.4% (3/56) of patients on each treatment arm did not receive any background medication due to intolerance.³
^‡A total of 4 patients randomly assigned to placebo were excluded from further analysis after the double-blind period (Week 0–16). Two patients decided to proceed with SRT, 1 patient withdrew consent, and 1 patient was found ineligible before the Week 16 visit.³

See the safety profile

Mavacamten safety profile

Please refer to the mavacamten Summary of Product Characteristics for further information on dosing, initiation and safety.

CI, confidence interval; LVOT, left ventricular outflow tract; NYHA, New York Heart Association; SoC, standard of care; SRT, septal reduction therapy.

References

Mavacamten Summary of Product Characteristics.
Desai MY et al. J Am Coll Cardiol. 2022;80(2):95–108.
Desai MY et al. JAMA Cardiol. 2023;8(10):968–977.

3500-GB-2600060 | March 2026